BioSig Technologies, Inc. announced that it has entered into a Securities Purchase Agreement with certain accredited and institutional investors, pursuant to which the Company sold to the Investors an aggregate of 1,458,770 shares of the company?s common stock, par value $0.001 per share at a purchase price of $0.5554 per share, and warrants to purchase up to 729,385 shares of common stock at an exercise price of $0.4929 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate gross proceeds of $810,201 on September 21, 2023. The Securities were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act.